Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRS-207 and Epacadostat in Platinum-Resistant Ovarian Cancer
NCT02575807Phase 2Terminated
- Sponsor
- Aduro Biotech, Inc.
- Start
- Mar 2016
- Primary completion
- Apr 2018
- Modality
- Oncolytic Viruses, Cell Therapies, Cancer Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of CRS-207 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Aduro Biotech, Inc.. Started Mar 2016; status: terminated.
02
Drugs
CRS-207
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02575807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575807.